• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/14/25 7:10:26 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HURA alert in real time by email
    8-K
    0001498382falseTuHURA Biosciences, Inc./NV00014983822025-11-142025-11-14

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 14, 2025

    TUHURA BIOSCIENCES, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

    Nevada

    001-37823

    99-0360497

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

    10500 University Center Dr., Suite 110

    Tampa, Florida 33612

    (Address of Principal Executive Offices, including zip code)

    Registrant’s Telephone Number, Including Area Code: (813) 875-6600

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

    Trading
    Symbol(s)


    Name of each exchange on which registered

    Common Stock, $0.001 par value per share

     

    HURA

    The Nasdaq Capital Market

     


     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On November 14, 2025, TuHURA Biosciences, Inc. (the “Company” or “TuHURA”) issued a press release reporting its financial results for the three months ended September 30, 2025, and providing a corporate update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein

     

    The information contained in this Current Report, including Exhibit 99.1 attached hereto, is being furnished, shall not be deemed “filed” for any purpose, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as expressly set forth by specific reference in such a filing.

     

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit

     

    No. Document

     

    99.1 Press Release, dated November 14, 2025

     

    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    TUHURA BIOSCIENCES, INC.

    Date:

    November 14, 2025

    By:

    /s/ Dan Dearborn

    Name: Dan Dearborn
    Title: Chief Financial Officer

     


    Get the next $HURA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HURA

    DatePrice TargetRatingAnalyst
    3/3/2025$13.00Buy
    H.C. Wainwright
    12/19/2024$11.00Buy
    Rodman & Renshaw
    11/5/2024$15.00Buy
    Maxim Group
    More analyst ratings

    $HURA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on TuHURA Biosciences with a new price target

    H.C. Wainwright initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $13.00

    3/3/25 7:23:43 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on TuHURA Biosciences with a new price target

    Rodman & Renshaw initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $11.00

    12/19/24 7:41:52 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on TuHURA Biosciences with a new price target

    Maxim Group initiated coverage of TuHURA Biosciences with a rating of Buy and set a new price target of $15.00

    11/5/24 7:54:57 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    SEC Filings

    View All

    SEC Form 10-Q filed by TuHURA Biosciences Inc.

    10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    11/14/25 7:20:46 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    11/14/25 7:10:26 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by TuHURA Biosciences Inc.

    D - TuHURA Biosciences, Inc./NV (0001498382) (Filer)

    11/10/25 4:07:26 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Tendler Craig

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    3/19/25 7:13:50 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Tendler Craig claimed no ownership of stock in the company (SEC Form 3)

    3 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    3/19/25 7:12:21 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hoffman Robert E.

    4 - TuHURA Biosciences, Inc./NV (0001498382) (Issuer)

    1/6/25 5:08:15 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

    Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing

    11/14/25 7:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition

    Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer immunotherapy The first demonstration that DOR is expressed on Tumor-Associated Macrophages (TAMs), with DOR inhibition modulating their immunosuppressive capabilities Presentation from The Moffitt Cancer Center in collaboration with TuHURA scientists demonstrating the presence of the DOR on MDSCs from patients with myeloid dysplastic syndrome (MDS) and restoration of stem cell proliferation with DOR inhibition TAMPA

    11/3/25 9:01:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference

    TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City. James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows: 27th Annual H.C. Wainwright Global Investment Conference Date: Monday, September 8, 2025 Time: 2:30 PM Eastern Time Link: Click Here A replay of the presenta

    8/20/25 8:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:30:14 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:28:34 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by TuHURA Biosciences Inc.

    SC 13G - TuHURA Biosciences, Inc./NV (0001498382) (Subject)

    10/25/24 4:26:02 PM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Leadership Updates

    Live Leadership Updates

    View All

    TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

    Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) Company's Delta Opioid Receptor (DOR) technology selected for an oral presentation, along with 2 poster presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting and Exposition, taking place in Orlando, Florida on December 6-9, 2025 TAMPA, Fla., Nov. 14, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing

    11/14/25 7:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management

    Proven 20-year career in drug discovery and development track record leading to 12 pre-clinical/clinical candidates and 7 investigational new drug / clinical trial applications Extensive knowledge in the biochemistry and pharmacology of the Delta Opioid Receptor (DOR), the primary target in TuHURA's Antibody Drug Conjugate (ADC) and Antibody Peptide Conjugate (APC) technology platform Inventor of first-in-class spirocyclic DOR agonists as potential analgesics; clinical- stage products licensed to Pfizer Led the benevopran opioid-induced bowel dysfunction program to positive Phase IIb results: key value inflection point resulting in the acquisition of Adolor Corporation by Cubist Pharmaceutic

    4/7/25 8:24:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HURA
    Financials

    Live finance-specific insights

    View All

    TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

    Phase 3 IFx-2.0 accelerated approval trial as adjunctive therapy with Keytruda® (pembrolizumab) in 1st line therapy for advanced Merkel cell carcinoma (MCC) planning to initiate enrollment in Q2 2025 MCC Phase 3 trial to be conducted under Special Protocol Assessment (SPA) Agreement with FDA Acquisition of Kineta's Phase 2 ready, VISTA inhibiting antibody targeted for completion in Q2 2025 Expanded discovery team for first-in-class immune modulating Antibody Drug or Peptide Conjugate Program TAMPA, Fla., April 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overco

    4/1/25 8:00:00 AM ET
    $HURA
    Biotechnology: Pharmaceutical Preparations
    Health Care